The upcoming advisory committee reviews of the first coronavirus vaccine(s) and Biogen, Inc.’s aducanumab for Alzheimer’s should be two historic panel meetings, prompting a look back at the greatest FDA advisory committees of the last 20 years. (Here’s Part I.)
For the Part II in the series, we focus on one committee meeting because it deserves special attention: two-in-one reviews of ILEX’ Clolar and Inex/Enzon’s Marqibo by the Oncologic Drugs Advisory Committee in 2004
Read the full article – start your free trial today!
Join thousands of industry professionals who rely on Pink Sheet for daily insights
- Start your 7-day free trial
- Explore trusted news, analysis, and insights
- Access comprehensive global coverage
- Enjoy instant access – no credit card required
Already a subscriber?